Main navigation | Main content
B.S., University of Wisconsin, Madison, WI, 2013
Honors and awards:
With increasing incidence of multiple drug resistant Mycobacterium tuberculosis (MDR-TB), there is a growing need for new or improved antibiotics to treat tuberculosis infections. Antifolates are a promising class of drug currently used as salvage therapy for MDR-TB. Antifolates disrupt the biosynthesis of tetrahydrofolate, an essential cofactor involved in one-carbon metabolism. Inhibition of one carbon metabolism deprives cells of many essential metabolites including dTTPs, purines, and several amino acids. The focus of my research is to understand the impacts of antifolate treatment on M. tuberculosis in an effort to improve drug efficacy, restore susceptibility in resistant strains, and prevent emergence of new antibiotic resistance. My research will also encompass pursuit of chemical compounds that can enhance or restore susceptibility to antifolates.